However, PD-L1/PD-1 specific antibody therapy alone was insufficient to induce an anti-tumor T-cell response in neuroblastoma of murine model, but in combination with BLZ945, a selective inhibitor of colony stimulating factor (CSF)-1 receptor, it was able to block MDSCs induced tumor progression [46], suggesting the reliability of combinational therapies. This evidence concerns the gene PDCD1 and neoplasm.